PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34020950-2	2021	We developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent.	Simurosertib	47-54	cell division cycle 7	Homo sapiens	31-35	
31131319-0	2019	Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.	Simurosertib	55-62	cell division cycle 7	Homo sapiens	72-76	
31131319-3	2019	We have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug.	Simurosertib	52-59	cell division cycle 7	Homo sapiens	26-30